Clinical characteristics of the study population
| Complete follow-up data by 2 years after transplantation . | Cohort 1: 1 mo of ACV . | Cohort 2: 1 yr of ACV . | Cohort 3: over 1 yr of ACV . |
|---|---|---|---|
| Number | 932 | 1117 | 586 |
| Age, y, median (range) | 42 (1-68) | 45 (1-74) | 47 (0-73) |
| Male | 487 (52.3) | 576 (51.6) | 358 (61.1) |
| Ethnicity | |||
| White | 801 (85.9) | 898 (80.4) | 476 (81.2) |
| Not white | 131 (14.1) | 219 (19.6) | 101 (17.2) |
| Missing | 0 (0) | 0 (0) | 9 (1.5) |
| Type of transplant procedure | |||
| Tandem transplant* | 17 (1.8) | 27 (2.4) | 15 (2.6) |
| Single autologous transplantation | 196 (21.0) | 262 (23.5) | 184 (31.4) |
| Single allogeneic transplantation | 719 (77.1) | 828 (74.1) | 387 (66.0) |
| Tandem strategy | |||
| Autologous–allogeneic | 1 (0.1) | 23 (2.1) | 15 (2.6) |
| Autologous–autologous | 16 (1.7) | 4 (0.4) | 0 (0) |
| Conditioning regimen | |||
| Nonmyeloablative† | 6 (0.6) | 126 (11.3) | 82 (14.0) |
| Myeloablative with TBI | 383 (41.1) | 513 (45.9) | 335 (57.2) |
| Myeloablative with combination chemotherapy | 526 (56.4) | 451 (40.4) | 154 (26.3) |
| Tandem | |||
| Myeloablative–myeloablative | 1 (0.1) | 23 (2.1) | 15 (2.6) |
| Myeloablative–nonmyeloablative | 16 (1.7) | 4 (0.4) | 0 (0) |
| Donor status | |||
| Autologous transplantation | 212 (22.7) | 266 (23.8) | 184 (31.4) |
| HLA-matched | 319 (34.2) | 424 (38.0) | 165 (28.2) |
| HLA-mismatched | 73 (7.8) | 33 (3.0) | 23 (3.9) |
| Unrelated | 328 (35.2) | 394 (35.3) | 214 (36.5) |
| Type of transplanted cells | |||
| Bone marrow | 597 (64.1) | 391 (35.0) | 69 (11.8) |
| Cord blood | 8 (0.9) | 12 (1.1) | 8 (1.4) |
| PBSC | 327 (35.1) | 714 (63.9) | 509 (86.9) |
| Underlying disease prognosis‡ | |||
| Good prognosis | 336 (36.1) | 396 (35.5) | 149 (25.4) |
| Poor prognosis | 596 (63.9) | 712 (63.7) | 425 (72.5) |
| Unknown | 0 (0) | 9 (0.8) | 12 (2.0) |
| Recipient HSV serostatus | |||
| Negative | 250 (26.8) | 213 (19.1) | 109 (18.6) |
| Positive | 677 (72.6) | 898 (80.4) | 474 (80.9) |
| Unknown | 5 (0.5) | 6 (0.5) | 3 (0.5) |
| Recipient/donor CMV serostatus in allogeneic recipients | |||
| −/− | 272 (37.8) | 280 (32.9) | 129 (32.1) |
| −/+ | 115 (16.0) | 120 (14.1) | 47 (11.7) |
| +/− | 152 (21.1) | 213 (25.0) | 117 (29.1) |
| +/+ | 180 (25.0) | 230 (27.0) | 108 (26.9) |
| Donor CMV serostatus unknown (recipient negative) | 1 (0.1) | 8 (1.0) | 1 (0.2) |
| Donor CMV serostatus autologous patients | |||
| Negative | 100 (47.2) | 119 (44.7) | 81 (44.0) |
| Positive | 112 (52.8) | 147 (55.3) | 103 (56.0) |
| Complete follow-up data by 2 years after transplantation . | Cohort 1: 1 mo of ACV . | Cohort 2: 1 yr of ACV . | Cohort 3: over 1 yr of ACV . |
|---|---|---|---|
| Number | 932 | 1117 | 586 |
| Age, y, median (range) | 42 (1-68) | 45 (1-74) | 47 (0-73) |
| Male | 487 (52.3) | 576 (51.6) | 358 (61.1) |
| Ethnicity | |||
| White | 801 (85.9) | 898 (80.4) | 476 (81.2) |
| Not white | 131 (14.1) | 219 (19.6) | 101 (17.2) |
| Missing | 0 (0) | 0 (0) | 9 (1.5) |
| Type of transplant procedure | |||
| Tandem transplant* | 17 (1.8) | 27 (2.4) | 15 (2.6) |
| Single autologous transplantation | 196 (21.0) | 262 (23.5) | 184 (31.4) |
| Single allogeneic transplantation | 719 (77.1) | 828 (74.1) | 387 (66.0) |
| Tandem strategy | |||
| Autologous–allogeneic | 1 (0.1) | 23 (2.1) | 15 (2.6) |
| Autologous–autologous | 16 (1.7) | 4 (0.4) | 0 (0) |
| Conditioning regimen | |||
| Nonmyeloablative† | 6 (0.6) | 126 (11.3) | 82 (14.0) |
| Myeloablative with TBI | 383 (41.1) | 513 (45.9) | 335 (57.2) |
| Myeloablative with combination chemotherapy | 526 (56.4) | 451 (40.4) | 154 (26.3) |
| Tandem | |||
| Myeloablative–myeloablative | 1 (0.1) | 23 (2.1) | 15 (2.6) |
| Myeloablative–nonmyeloablative | 16 (1.7) | 4 (0.4) | 0 (0) |
| Donor status | |||
| Autologous transplantation | 212 (22.7) | 266 (23.8) | 184 (31.4) |
| HLA-matched | 319 (34.2) | 424 (38.0) | 165 (28.2) |
| HLA-mismatched | 73 (7.8) | 33 (3.0) | 23 (3.9) |
| Unrelated | 328 (35.2) | 394 (35.3) | 214 (36.5) |
| Type of transplanted cells | |||
| Bone marrow | 597 (64.1) | 391 (35.0) | 69 (11.8) |
| Cord blood | 8 (0.9) | 12 (1.1) | 8 (1.4) |
| PBSC | 327 (35.1) | 714 (63.9) | 509 (86.9) |
| Underlying disease prognosis‡ | |||
| Good prognosis | 336 (36.1) | 396 (35.5) | 149 (25.4) |
| Poor prognosis | 596 (63.9) | 712 (63.7) | 425 (72.5) |
| Unknown | 0 (0) | 9 (0.8) | 12 (2.0) |
| Recipient HSV serostatus | |||
| Negative | 250 (26.8) | 213 (19.1) | 109 (18.6) |
| Positive | 677 (72.6) | 898 (80.4) | 474 (80.9) |
| Unknown | 5 (0.5) | 6 (0.5) | 3 (0.5) |
| Recipient/donor CMV serostatus in allogeneic recipients | |||
| −/− | 272 (37.8) | 280 (32.9) | 129 (32.1) |
| −/+ | 115 (16.0) | 120 (14.1) | 47 (11.7) |
| +/− | 152 (21.1) | 213 (25.0) | 117 (29.1) |
| +/+ | 180 (25.0) | 230 (27.0) | 108 (26.9) |
| Donor CMV serostatus unknown (recipient negative) | 1 (0.1) | 8 (1.0) | 1 (0.2) |
| Donor CMV serostatus autologous patients | |||
| Negative | 100 (47.2) | 119 (44.7) | 81 (44.0) |
| Positive | 112 (52.8) | 147 (55.3) | 103 (56.0) |
Data are numbers (%) except for rows 1 and 2.
CMV indicates cytomegalovirus; PBSC, peripheral blood stem cells; and TBI, total body irradiation.
Tandem regimens combine two transplantation procedures, autologous transplantation with subsequent autologous or nonmyeloablative allogeneic transplantation (auto–auto or auto–allo).
Nonmyeloablative regimen includes TBI 200 cGy alone or fludarabine (90 mg/m2) plus TBI (200 cGy).
Low-risk disease included chronic myeloid leukemia in chronic phase and hematomalignancy in first remission aplastic anemia. High-risk disease included refractory anemia, chronic lymphoid leukemia, paroxysmal nocturnal hemoglobinuria, chronic leukemia in blast phase, juvenile chronic leukemia, hematologic malignancy in relapse, multiple myeloma, myeloid metaplasia, and solid organ tumor.